GlassScriptPhysician profile
Christopher Eric Hudak
NPI 1831366954
$12,468.37
in general payments reported to CMS, 2019-2025
67 companies · $2,867 in 2025
The $2,867 reported for 2025 was more than what 82% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,201 · 2020: $12.60 · 2021: $820 · 2022: $2,615 · 2023: $1,882 · 2024: $2,070 · 2025: $2,867.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,756 · Education: $63.60.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,756.29 |
| Education | $63.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tandem Diabetes Care, INC. | $1,492.00 | 2019-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Novo Nordisk INC | $904.06 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Mannkind Corporation | $881.38 | 2019-2025 | Afrezza |
| Lilly USA, LLC | $832.79 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Amgen INC. | $779.54 | 2019-2025 | Tepezza, Evenity, Prolia |
| Astrazeneca Pharmaceuticals LP | $591.59 | 2019-2023 | Farxiga |
| Bayer Healthcare Pharmaceuticals INC. | $477.94 | 2022-2025 | |
| Sanofi-Aventis U.S. LLC | $379.52 | 2019-2025 | |
| Xeris Pharmaceuticals, INC. | $366.26 | 2021-2025 | Recorlev, Gvoke Hypopen |
| Dexcom, INC. | $361.17 | 2019-2025 | Dexcom G6 Transmitter |
| Medtronic, INC. | $326.11 | 2022-2025 | Minimed 780g, Inpen Smart Insulin Delivery System |
| Antares Pharma, INC. | $297.41 | 2019-2025 | Xyosted, Tlando, Nocdurna |
| Recordati_rare_diseases_inc. | $290.21 | 2022-2024 | Signifor Lar, Isturisa |
| Abbott Laboratories | $246.65 | 2019-2025 | Freestyle Libre 3 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $219.67 | 2022-2025 | Jardiance |
Show all 67 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Insulet Corporation | $208.09 | 2021-2025 | Omnipod |
| Neurocrine Biosciences, INC. | $196.26 | 2024-2025 | |
| Madrigal Pharmaceuticals | $192.17 | 2025 | Rezdiffra |
| Cequr Corporation | $187.09 | 2022-2025 | Cequr Simplicity |
| Corcept Therapeutics | $184.36 | 2022-2025 | Korlym |
| Medtronic Minimed, INC. | $183.96 | 2019-2020 | |
| Radius Health, INC. | $168.78 | 2019-2025 | Tymlos |
| Abbvie INC. | $157.32 | 2019-2024 | |
| Ibsa Pharma INC. | $143.57 | 2021-2025 | Tirosint, Tirosint, Flector |
| Alexion Pharmaceuticals, INC. | $141.07 | 2022-2025 | Strensiq |
| Amarin Pharma, INC. | $137.60 | 2019-2023 | |
| Acella Pharmaceuticals, LLC | $132.31 | 2022-2025 | NP Thyroid 60 |
| Amneal Pharmaceuticals LLC | $129.39 | 2019-2023 | Unithroid |
| Esperion Therapeutics, INC. | $127.75 | 2022-2025 | Nexletol |
| Verity Pharmaceuticals INC. | $126.34 | 2024-2025 | Tlando |
| Ascensia Diabetes Care US INC. | $105.69 | 2024-2025 | |
| Sequel Med Tech, LLC | $96.97 | 2025 | Twiist |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $92.26 | 2022-2023 | Cycloset |
| Beta Bionics, INC. | $92.12 | 2023-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Ascendis Pharma Endocrinology INC | $87.22 | 2023-2025 | Yorvipath |
| Merck Sharp & Dohme LLC | $75.34 | 2021-2022 | |
| Eusa Pharma (US) LLC | $73.05 | 2022 | |
| Boston Scientific Corporation | $72.49 | 2025 | Wavewriter Alpha Prime 16 |
| Pfizer INC. | $65.61 | 2021-2023 | |
| Tolmar, INC. | $64.60 | 2023-2025 | Jatenzo |
| Soleno Therapeutics, INC. | $62.44 | 2025 | Vykat Xr |
| Ultragenyx Pharmaceutical INC. | $56.92 | 2021-2022 | |
| Regeneron Healthcare Solutions, INC. | $56.24 | 2024-2025 | Evkeeza, Praluent |
| Avvisto Therapeutics, LLC | $47.80 | 2024-2025 | Cycloset |
| Astellas Pharma US INC | $39.66 | 2025 | Veozah |
| Amryt Pharma Holdings LTD | $38.02 | 2023 | Mycapssa |
| Zealand Pharma US, INC. | $34.07 | 2022 | |
| Novartis Pharmaceuticals Corporation | $34.00 | 2022-2023 | |
| Alvogen INC | $33.52 | 2022-2025 | Teriparatide |
| Amphastar Pharmaceuticals, INC. | $31.59 | 2025 | |
| Shire North American Group INC | $29.76 | 2019 | |
| Rhythm Pharmaceuticals, INC. | $29.43 | 2024 | Imcivree |
| Sandoz INC. | $27.49 | 2025 | |
| Lifescan, INC. | $27.28 | 2019-2022 | |
| Abiomed | $24.45 | 2024 | Impella |
| Companion Medical, INC. | $24.39 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $23.14 | 2023 | Livalo |
| Clarus Therapeutics INC. | $22.29 | 2021 | |
| Horizon Therapeutics Plc | $21.02 | 2023 | Tepezza |
| Strongbridge US INC. | $20.16 | 2019 | |
| Chiesi USA, INC. | $17.06 | 2025 | Mycapssa |
| Evoke Pharma, INC. | $16.12 | 2024 | |
| Halozyme INC | $14.14 | 2023 | |
| Vivus LLC | $13.63 | 2021 | |
| Currax Pharmaceuticals LLC | $12.40 | 2021 | |
| Nevro Corp. | $11.97 | 2022 | |
| Roche Diabetes Care, INC. | $11.67 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Hudak listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.